ArticleThe Journal of infectious diseases2012
Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection.
Article in The Journal of infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 60 citations in OpenAlex.
- Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes.Fertility and sterility · 2015Trial
- Immunological evaluation of vaccines to prevent Chlamydia trachomatis infection using the human in vitro MIMIC system.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Serum IgG1 and IgG3 Antibodies to Chlamydia trachomatis Pgp3 and Hsp60 in Men of Subfertile Couples.The Journal of infectious diseases · 2026Article
- Serum IgG1 and IgG3 Antibody Responses to Chlamydia trachomatis Pgp3 and Hsp60 in Tubal Factor Infertility.The Journal of infectious diseases · 2025Article
- Risk factors associated with IgG seropersistence toEpidemiology and infection · 2025Article
- Prevalence and risk factors for Chlamydia trachomatis seropositivity and seropersistence among women: A prospective cohort study.PloS one · 2025Article
- Screening for STIs: Results of a Health-Promotion Programme in a Portuguese University.Microorganisms · 2024Article
- Comparison of IgG serum antibodies, electronic health records and self-report in estimating past infection withSexual health · 2024Article
- Chlamydia trachomatis Seroassays Used in Epidemiologic Research: A Narrative Review and Practical Considerations.The Journal of infectious diseases · 2024Review
- Antibodies from chlamydia-infected individuals facilitate phagocytosis via Fc receptors.Infection and immunity · 2024Article
- In silico design and analysis of a multiepitope vaccine against Chlamydia.Pathogens and disease · 2024Article
- Trends inSexually transmitted infections · 2024Article
- The serodiagnositic value ofFrontiers in public health · 2024Article
- Antibody responses toFrontiers in cellular and infection microbiology · 2024Article
- Redefining serological diagnostics with immunoaffinity proteomics.Clinical proteomics · 2023Review
- Oil-based or saline contrast for sono-hysterosalpingography in infertile women: a pilot randomized controlled double blind trial.F&S reports · 2023Article
- What Can Serology Tell Us About the Burden of Infertility in Women Caused by Chlamydia?The Journal of infectious diseases · 2021Review
- Seroepidemiology ofFrontiers in microbiology · 2021Article
- Antibodies to Variable Domain 4 Linear Epitopes of themSphere · 2020Article
- Shift work influences the outcomes of Chlamydia infection and pathogenesis.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Renewed interest in chlamydia vaccination has revealed the need for a greater understanding of the seroprevalence of chlamydial infection in US populations. We used a Chlamydia trachomatis elementary body (EB)-based enzyme-linked immunosorbent assay to define the characteristics of the humoral immune response and to determine seroprevalence. Two groups were analyzed: one consisting of patients with current, laboratory confirmed, genital chlamydial infection (n = 98) and one group of individuals whose chlamydia infection history was unknown (n = 367). C. trachomatis seropositivity was detected in 90% of the infected group and in 31% of the chlamydia-unknown group. IgG1 and IgG3 comprised the predominant anti-Chlamydia serum antibody responses. Serum IgA1 responses were variably positive, and individuals were rarely positive for anti-chlamydia IgG2, IgG4 or IgA2. The magnitude of the IgG1 and IgG3 responses was greatest in female and African American individuals and was sustained for at least 6 months. Antibody responses were not serovar restricted or confounded by Chlamydia pneumoniae cross-reactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.